Category : Seeking Alpha

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

Skycorp Solar Group Announces Board Authorization for Solar Photovoltaic Power Plant Acquisitions and Development

Ningbo, China, July 03, 2025 (GLOBE NEWSWIRE) -- Skycorp Solar Group Limited (the “Company”) (NASDAQ: PN), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, today announced that its Board of Direc...

Skyharbour’s Partner Company Mustang Energy Receives Exploration Permit for 914W Uranium Project Located in the Athabasca Basin, Saskatchewan

Vancouver, BC, July 03, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is pleased to announce that partner company Mustang Energy Corp. (“Mustang”) has received explo...

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

Locafy Receives Nasdaq Notification Regarding Delayed Filing of Interim Financials

PERTH, Australia, July 03, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (NASDAQ: LCFY, “Locafy” or the “Company”), a globally recognized leader in location-based digital marketing, today announced that on July 1, 2025, it received a notice from the Nasd...

Netcapital Announces Up To $9.9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$5 million upfront with up to an additional $4.9 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

La Rosa Holdings Corp. Announces Significant Milestone: Surpasses 3,000 Agents and Reports Preliminary Unaudited Revenue of $38.4 Million for the First Half of 2025, Achieving 19.4% Year-Over-Year Growth

Celebration, FL, July 03, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today announced a major milestone in its growth trajectory, surpassing 3,000 real estate agen...

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

Parex Resources Announces Production Update and Timing of Q2 2025 Results

CALGARY, Alberta, July 03, 2025 (GLOBE NEWSWIRE) -- Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) announces a production update and plan to release its Q2 2025 financial and operating results on July 30, 2025.

MAAS Announces A Private Placement of Class A Ordinary Shares and Warrants

CHENGDU, China, July 03, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the execution of a definitive share purchase agreement (the “Agreement”) with certain investors, pursuant to which the investors h...

American Rebel Light Beer Congratulates John Hall on Triumphant NHRA Victory in Ohio

Hall Scores First Pro Stock Motorcycle Win in Nearly 12 Years

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable